Drug intelligence / Profile preview

YHP2406

Development stage: Phase 1
Lead developer: Yuhan
Modality: Small Molecules
Administration: Oral

Overview

YHP2406 is an **oral therapeutic candidate** being developed by **Yuhan**. It is currently the subject of a phase 1, open-label, randomized, single-dose, two-sequence, two-period, crossover clinical trial to evaluate **bioequivalence** with YHR2501 in healthy subjects. The specific disease indication for YHP2406 has not been disclosed publicly. The mechanism of action and molecular details have not been made available. The drug is being studied for safety, pharmacokinetics, and bioequivalence compared to YHR2501, but its intended clinical use and target(s) remain undisclosed[1][3][5][7].

Beyond the preview

Go deeper on YHP2406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YHP2406.

Explore the full profile